I

    InMed Pharmaceuticals Inc (INM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.35
    -0.03 (-2.17%)

    Market Cap: $7.37M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(12/21)
    Avg Surprise
    -18.16%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26
    		$-0.73N/AN/ABeat+62.1%
    Dec 25
    		$-0.51N/AN/ABeat+85.9%
    Sep 25
    		$-0.44N/AN/ABeat-101.0%
    Jun 25
    		$-1.20N/AN/ABeat-452.2%
    Mar 25
    		$-1.94N/AN/ABeat-979.9%
    Dec 24
    		$-3.64N/AN/ABeat+74.0%
    Sep 24
    		$-0.22$0.00N/ABeat-113.7%
    Jun 24
    		$-0.22$0.00N/ABeat+93.3%
    Mar 24
    		$-0.18$-0.18+0.44%Beat+70.1%
    Dec 23
    		$-14.03$-5.50-155.09%Miss-1441.8%
    Sep 23
    		$-0.10N/A+53.77%Beat+99.9%
    Jun 23
    		$-3.25$-4.25+23.53%Beat+76.8%
    Mar 23
    		$-0.60N/A+86.67%Beat+99.6%
    Dec 22
    		$-0.91N/A+79.78%Beat+99.5%
    Sep 22
    		$-107.86$-108.50+0.59%Beat+30.6%
    Jun 22
    		$-14.03$-5.50-155.09%Miss-36.9%
    Mar 22
    		$-161.65$-159.50-1.35%Miss+21.1%
    Dec 21
    		$-197.45$-149.50-32.07%Miss-6.7%
    Sep 21
    		$-155.49$-222.00+29.96%Beat-45632.4%
    Jun 21
    		$-10.25$-8.50-20.59%Miss+99.1%
    Mar 21
    		$-205.00$-152.50-34.43%Miss+37.9%
    Dec 20
    		$-185.00$-153.50-20.52%Miss+43.9%
    Sep 20
    		$-0.34N/A+97.94%Beat+99.9%
    Jun 20
    		$-1105.00$-330.00-234.85%Miss-167324.2%
    Mar 20
    		$-330.00$-330.00+0.00%Beat+0.0%
    Dec 19
    		$-330.00$-330.00+0.00%Beat-84951.5%
    Sep 19
    		$-330.00$-330.00+0.00%Beat-78490.1%
    Jun 19
    		$-0.66$-0.66+0.00%Beat-32.3%
    Mar 19
    		$-330.00$-165.00-100.00%Miss-89965.5%
    Dec 18
    		$-0.39N/AN/ABeat-28.3%
    Sep 18
    		$-0.42N/AN/ABeat-14.7%
    Jun 18
    		$-0.50N/AN/ABeat+99.7%
    Mar 18
    		$-0.37N/AN/ABeat-34.8%
    Dec 17
    		$-0.30N/AN/ABeat-21.2%
    Sep 17
    		$-0.37N/AN/ABeat-149.9%
    Jun 17
    		$-180.36N/AN/ABeat-
    Mar 17
    		$-0.27N/AN/ABeat-
    Dec 16
    		$-0.25N/AN/ABeat-
    Sep 16
    		$-0.15N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.47EV/EBITDA0.51x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-172.20%Operating Margin-162.70%
    ROE-112.70%ROIC-93.23%
    Financial Health
    Debt/Equity0.06xInterest CoverageN/A
    Current Ratio3.11xQuick Ratio3.11x
    Trading Statistics
    Beta0.98Avg Volume84.84K
    52-Week High$2.5052-Week Low$0.57

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.45
    SMA 20$1.45
    SMA 50$1.53
    SMA 200$1.19
    EMA 10$1.43
    EMA 20$1.46
    EMA 50$1.46
    EMA 200$1.44

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 21.6+DI: 15.2-DI: 18.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.63

    Bollinger Bands

    Upper Band$1.56
    Lower Band$1.34
    %B Position1557%(Upper)
    Band Width0.06

    RSI (14-Day)

    Neutral
    38.8

    Momentum Oscillators

    Stoch %K11.2
    Stoch %D19.7
    Williams %R-100.0
    ROC (10d)-7.5%
    Momentum-0.11
    CCI (20d)-147.0
    MFI (14d)46.6

    Volatility Measures

    ATR (14d)$0.11(8.3%)
    StdDev (20d)0.06
    Hist Vol61.1%(High)

    Volume Flow

    VWAP$1.37
    OBV329.9M
    AD Line-154.3M
    CMF (20d)-0.420

    Volume Metrics

    Avg Vol (20d)85.9K
    Vol Ratio1.0x
    VWMA (20d)$1.44

    Pivot Points

    R3$1.46
    R2$1.45
    R1$1.41
    Pivot Point$1.40
    S1$1.36
    S2$1.35
    S3$1.31

    Advanced Oscillators

    TSI-10.80
    Ultimate Osc28.5
    KST-69.25

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$820,188$1.12M$1.30M$0$1.11M$1.26M$1.28M$1.17M$1.24M$901,862$2.31M
    Cost of Revenue$0$635,994$716,962$728,056$0$650,813$771,225$816,996$883,143$916,058$880,620$1.32M
    Gross Profit$0$184,194$403,159$576,654$0$460,894$493,413$466,071$289,458$324,142$21,242$1.57M
    Operating Expenses$2.82M$2.30M$2.17M$2.42M$2.06M$2.67M$2.25M$2.48M$2.09M$2.03M$2.65M$1.51M
    R&D$1.02M$630,636$581,612$112,720$425,370$895,176$700,145$658,869$656,764$609,791$1.29M$623,744
    SG&A$1.74M$1.62M$1.53M$2.25M$1.58M$1.72M$1.49M$1.76M$1.37M$1.36M$1.30M$1.41M
    Operating Income$-2,816,353$-2,120,738$-1,763,670$-1,842,135$-2,061,469$-2,206,258$-1,754,272$-2,009,007$-1,796,168$-1,704,841$-2,624,414$-516,262
    Interest Income$47,770$74,379$93,765$51,687$16,565$30,536$57,094$103,640$121,458$166,760$136,043$148,559
    Interest Expense$0$0$0$0$5,600$368,766$0$0$0$0$0$0
    Income Before Tax$-2,791,751$-2,028,223$-1,726,899$-1,788,311$-2,067,069$-2,575,024$-1,677,868$-1,930,571$-1,722,866$-1,478,185$-2,536,828$-336,591
    Income Tax Expense$0$0$0$0$0$0$0$7,100$0$0$0$0
    Net Income$-2,966,336$-2,028,223$-1,726,899$-1,788,311$-2,120,930$-2,575,024$-1,677,868$-1,937,671$-1,722,866$-1,478,185$-2,536,828$-338,391
    EBITDA$-2,706,063$-1,962,719$-1,663,984$-1,758,775$-1,954,051$-2,476,481$-1,589,982$-1,820,429$-1,789,554$-1,589,714$-2,523,507$-365,290
    EBIT$-2,839,521$-2,120,738$-1,820,664$-1,811,527$-2,083,634$-2,605,560$-1,734,962$-1,972,290$-1,844,324$-1,644,945$-2,672,871$-516,262
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INM

    News

    InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

    Ikarian Capital, LLC and Neil Shahrestani have jointly reported a 4.2% beneficial ownership stake in InMed Pharmaceuticals Inc. (INM), totaling 137,634 common shares. This ownership, held through Ikarian Healthcare Master Fund, L.P. and separately managed accounts, is based on 3,314,063 common shares outstanding as of May 4, 2026. The reporting persons share voting and dispositive power over these shares, and the filing includes standard disclaimers regarding group status.

    Stock Titan•8/15/26•
    Neutral

    InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis

    This article analyzes the financial health of InMed Pharmaceuticals Inc (INM), ranking it 190 out of 384 in the Biotechnology & Medical Research industry with a current financial score of 6.87. It notes the company's robust financial status but low operating efficiency. The report highlights that relevant financial data for key metrics like cash and cash equivalents, revenue, operating profit, and cash flow from operations have not yet been disclosed by the company.

    TradingKey•7/30/26•
    Somewhat-Bearish

    InMed Pharmaceuticals Inc (INM) Institutional Confidence

    This article from TradingKey focuses on the institutional confidence score for InMed Pharmaceuticals Inc (INM), which is currently 3.00, unchanged from its previous score. It details the institutional shareholdings and recent changes in shares held by various entities like Sabby Management, LLC, Yorkville Advisors Global, LP, and Susquehanna International Group, LLP. The data indicates some institutional activity with both increases and decreases in holdings for different investment firms and individuals.

    TradingKey•7/27/26•
    Somewhat-Bearish

    INM|InMed Pharmaceuticals Inc|Price:1.580|Chg%:-0.130

    InMed Pharmaceuticals Inc. (INM) is a pharmaceutical company focused on developing small molecule drug candidates targeting CB1/CB2 receptors. Its pipeline includes potential treatments for Alzheimer's disease (INM-901), dry age-related macular degeneration (INM-089), and Epidermolysis Bullosa (INM-755), which has completed Phase 2 clinical trials. The company also has a BayMedica Commercial segment producing bulk rare cannabinoids.

    TradingKey•7/26/26•
    Neutral

    InMed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:INM

    InMed Pharmaceuticals Inc. (NASDAQ: INM) generated its greatest revenue contribution from Canada, totaling $4.94 million USD last year. This figure represents an increase from $4.60 million USD the previous year. The data provides a breakdown of the company's revenue by country, highlighting Canada as a primary source.

    TradingView•7/26/26•
    Neutral

    Frequently Asked Questions About INM

    Does INM pay dividends?
    InMed Pharmaceuticals Inc (INM) does not currently pay a regular dividend.
    What is INM's market cap?
    InMed Pharmaceuticals Inc (INM) has a market capitalization of $7.37M with a current stock price of $1.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In